Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the stock. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Barclays reiterated an “equal weight” rating and set a $7.00 target price (down from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Mizuho dropped their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a research report on Friday, November 8th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Revance Therapeutics presently has a consensus rating of “Hold” and an average target price of $8.96.

Revance Therapeutics Stock Down 0.3 %

Shares of NASDAQ RVNC opened at $3.08 on Thursday. Revance Therapeutics has a 52-week low of $2.30 and a 52-week high of $9.74. The business’s 50 day moving average is $4.60 and its two-hundred day moving average is $4.46. The firm has a market cap of $323.09 million, a price-to-earnings ratio of -1.60 and a beta of 0.81.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $67.73 million. Analysts anticipate that Revance Therapeutics will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Revance Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Certuity LLC acquired a new position in shares of Revance Therapeutics during the 2nd quarter worth about $26,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Revance Therapeutics during the second quarter worth approximately $33,000. Hsbc Holdings PLC acquired a new position in Revance Therapeutics in the second quarter valued at approximately $38,000. Nisa Investment Advisors LLC increased its stake in Revance Therapeutics by 2,167.5% in the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 18,077 shares during the last quarter. Finally, FORA Capital LLC acquired a new stake in Revance Therapeutics during the third quarter worth approximately $54,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.